Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Market Insights 2022: Coverage of 15 Companies and Respective Pipeline Drugs - ResearchAndMarkets.com

The "Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist" clinical trials has been added to ResearchAndMarkets.com's offering.

This Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2022 report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist. The therapies under development are focused on novel approaches to treat/improve Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist.

This segment of the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Emerging Drugs

Pemigatinib: Incyte Corporation

Pemigatinib is an orally bioavailable, small molecule, and selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3 and 4. Pemigatinib is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy.

H3B-6527: H3 biomedicine

H3B-6527 is a selective, orally bioavailable, and covalent inhibitor of FGFR4 that has demonstrated tumor regression in several preclinical models of HCC. Receptor tyrosine kinases (RTKs) can be dysregulated in cancer cells and can frequently promote abnormally rapid tumor growth and development. Hepatocellular carcinoma (HCC) can be driven in this way by hyperactivation of the fibroblast growth factor receptor 4 (FGFR4). H3B-6527 is being tested specifically in patients with FGFR4-dysregulated advanced HCC.

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Therapeutic Assessment

This segment of the report provides insights about the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist

There are approx. 15+ key companies which are developing the therapies Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist. The companies which have their Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drug candidates in the most advanced stage, i.e Phase III include, Helsinn.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs.

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Report Insights

• Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Players

• H3 Biomedicine
• AiViva BioPharma
• Incyte Corporation
• Helsinn
• Astellas Pharma
• Taiho Oncology
• Eli Lilly and Company

Key Players

• H3B 6527
• Lenvatinib
• Pemigatinib
• Infigratinib
• ASP-5878
• Futibatinib
• LY 2874455

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/eiajo1

View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005612/en/